Renhe Pharmacy Co

Renhe Pharmacy Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Renhe Pharmacy Co (000650.SZ) as of Oct 19, 2026 is 9.27 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 10.36 % — a change of -10.54% (lower).

EBIT/Assets

9.27 %

YoY

-10.54%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Renhe Pharmacy Co is 2025 9.27 % . Operating Income to Assets Ratio (EBIT/Assets) of Renhe Pharmacy Co was 2024 10.36 % . It decreases by -10.54% lower compared to the previous year.

The Renhe Pharmacy Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
16.31 CNY
Jan 1, 2019
16.58 CNY
Jan 1, 2020
13.98 CNY
Jan 1, 2021
15.01 CNY
Jan 1, 2022
12.49 CNY
Jan 1, 2023
12.07 CNY
Jan 1, 2024
10.36 CNY
Jan 1, 2025
9.27 CNY
The Renhe Pharmacy Co EBIT/Assets history
YEAREBIT/AssetsYoY
9.27 %-10.54%
10.36 %-14.20%
12.07 %-3.36%
12.49 %-16.79%
15.01 %+7.35%
13.98 %-15.64%
16.58 %+1.64%
16.31 %+19.26%
13.67 %-3.95%
14.24 %-19.79%
17.75 %+10.99%
15.99 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renhe Pharmacy Co Stock analysis

What does Renhe Pharmacy Co do? Renhe Pharmacy Co Ltd is a pharmaceutical company based in Nanchang, China, operating within the Health Care sector. The company, listed on the Shenzhen Stock Exchange under ticker 000650.SZ, has been publicly traded since its IPO on December 10, 1996. Renhe Pharmacy employs 6,062 full-time staff and focuses on the manufacturing and distribution of pharmaceutical products. Its product portfolio includes various dosage forms such as capsules, granules, tablets, powders, injections, suppositories, and ointments. The company operates primarily within China, distributing its products domestically. Renhe Pharmacy is engaged in both the industrial manufacturing of pharmaceuticals and the retail and wholesale distribution of health-related products. The firm's headquarters are located in Nanchang, Jiangxi Province, and it maintains a website at https://www.renheyaoye.com/photography, though the content of the site is not detailed here. The company's activities are centered around the production and sale of pharmaceuticals, with no indication of international operations or significant acquisitions beyond the information provided. The business model emphasizes domestic market presence, serving both medical institutions and consumers through its product range. Renhe Pharmacy Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renhe Pharmacy Co stock

Operating Income to Assets Ratio (EBIT/Assets) of Renhe Pharmacy Co is 9.27 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Renhe Pharmacy Co changed from 10.36 % to 9.27 %, representing a -10.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Renhe Pharmacy Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Renhe Pharmacy Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Renhe Pharmacy Co

All Key Metrics — Renhe Pharmacy Co